← Back to Search

18F-FCH PET Scan for Brain Tumor

N/A
Waitlist Available
Led By Kathryn Beal, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is testing a new imaging agent to help distinguish between radiation-induced scarring and tumor regrowth in the brain.

Eligible Conditions
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
to distinguish radiation necrosis from progressive tumor

Trial Design

1Treatment groups
Experimental Treatment
Group I: pts with brain mets going for surgeryExperimental Treatment1 Intervention
This study will enroll patients with brain metastases that are evolving after SRS who are scheduled to undergo surgical resection. Eligible patients will undergo an 18F-FCH PET study 1-to-7 days pre-operatively. Although no toxicity has been previously reported following 18F-FCH administration, patients will be contacted 1-3 days after their scan and asked whether they experienced any adverse effects. The patients who have a positive 18F-FCH PET study (in which there is visible focal "hot spots" (a focus of lesion/normal white matter ratio >1.4) of 18F-FCH) will undergo further evaluation and be administered a second administration oflower activity 18F-FCH at the time of surgery. The purpose of the second 18F-FCH administration in the operating room is to further elucidate the tissue distribution of 18F-FCH radioactivity with respect to the histopathology of the surgically resected tissue.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-FCH PET Scan
2014
N/A
~20

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,936 Previous Clinical Trials
588,862 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,700 Previous Clinical Trials
7,506,857 Total Patients Enrolled
Kathryn Beal, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
81 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining openings for this research protocol?

"Clinicaltrials.gov records indicate that this medical trial, whose materials were last updated on February 1st 2022, is no longer actively recruiting patients. Nonetheless, 1948 other trials are looking for candidates right now."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases
2014. "18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02037945.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top